The 2008 WHO classification of lymphomas: implications for clinical practice and translational research.
The 2008 WHO classification of lymphomas: implications for clinical practice and translational research.
复制标题
DOI：
10.1182/asheducation-2009.1.523
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
Jaffe ES
中科院分区：
文献类型：
--
作者：
Jaffe ES
2008年出版的世卫组织造血和类造血组织肿瘤分类第4版是在2001年第3版成功的基础上建立的;定义了新的实体，并寻求有问题类别的解决方案。最近的研究引起了人们对经典霍奇金淋巴瘤（CHL）和弥漫性大B细胞淋巴瘤（DLBCL）之间生物学重叠的关注。同样，伯基特淋巴瘤和DLBCL之间的边界有更大的赞赏。这些边缘病变的管理策略提出。此外，特定年龄和特定地点的因素在确定几个新实体方面发挥着重要作用，这些实体也有生物学基础。在外周T细胞淋巴瘤（PTCL）中，对几种实体引入了更精确的定义，包括间变性大细胞淋巴瘤、血管免疫母细胞性T细胞淋巴瘤、肠病相关T细胞淋巴瘤和皮下脂膜炎样T细胞淋巴瘤。原发性皮肤T细胞淋巴瘤的几个新的变种提出。最后，改变了最常见的淋巴瘤亚型滤泡性淋巴瘤（FL）和DLBCL的亚分类和分类，以提高诊断准确性并有助于临床管理。2008年世卫组织分类也提请注意淋巴瘤发生的早期事件。这些病变有助于描述肿瘤转化的最早阶段，通常需要保守治疗。2001年的分类很快被临床试验采用，并成功地成为科学家比较遗传和功能数据的通用语言。2008年分类中所做的修改是病理学家、临床医生和生物学家成功合作的结果，但只是通往未来的垫脚石。
The 4th edition of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues published in 2008 builds upon the success of the 2001 3rd edition; new entities are defined, and solutions for problematic categories are sought. Recent studies have drawn attention to the biological overlap between classical Hodgkin lymphoma (CHL) and diffuse large B-cell lymphomas (DLBCL). Similarly, there is a greater appreciation of the borderlands between Burkitt lymphoma and DLBCL. Strategies for the management of these borderline lesions are proposed. Additionally, age-specific and site-specific factors play an important role in the definition of several new entities, which also have biological underpinnings. Among the peripheral T-cell lymphomas (PTCL), more precise definitions were introduced for several entities, including anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma, and subcutaneous panniculitis-like T-cell lymphoma. Several new variants of primary cutaneous T-cell lymphomas are proposed. Finally, the subclassification and categorization of the most common lymphoma subtypes, follicular lymphoma (FL) and DLBCL, were altered to enhance diagnostic accuracy and aid in clinical management. The 2008 WHO classification also draws attention to early events in lymphomagenesis. These lesions help delineate the earliest steps in neoplastic transformation and generally mandate a conservative therapeutic approach. The 2001 classification was rapidly adopted for clinical trials and successfully served as a common language for scientists comparing genetic and functional data. The modifications made in the 2008 classification are the result of this successful partnership among pathologists, clinicians, and biologists, but are only a stepping stone to the future.